C
Cecilia Anesi
Researcher at Università Campus Bio-Medico
Publications - 12
Citations - 899
Cecilia Anesi is an academic researcher from Università Campus Bio-Medico. The author has contributed to research in topics: Cancer & Performance status. The author has an hindex of 8, co-authored 11 publications receiving 445 citations.
Papers
More filters
Journal ArticleDOI
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
Alessio Cortellini,Melissa Bersanelli,Sebastiano Buti,Katia Cannita,Daniele Santini,Fabiana Perrone,Raffaele Giusti,Marcello Tiseo,Maria Michiara,Pietro Di Marino,Nicola Tinari,Michele De Tursi,Federica Zoratto,Enzo Veltri,Riccardo Marconcini,Francesco Malorgio,Marco Russano,Cecilia Anesi,Tea Zeppola,Marco Filetti,Paolo Marchetti,Andrea Botticelli,Gian Carlo Antonini Cappellini,Federica De Galitiis,Maria Giuseppa Vitale,Francesca Rastelli,Federica Pergolesi,Rossana Berardi,Silvia Rinaldi,Marianna Tudini,Rosa Rita Silva,Annagrazia Pireddu,Francesco Atzori,Rita Chiari,Biagio Ricciuti,Andrea De Giglio,Daniela Iacono,Alain Gelibter,Mario Occhipinti,Alessandro Parisi,Giampiero Porzio,Maria Concetta Fargnoli,Paolo A. Ascierto,Corrado Ficorella,Clara Natoli +44 more
TL;DR: Overweight could be considered a tumorigenic immune-dysfunction that could be effectively reversed by ICIs and BMI could be a useful predictive tool in clinical practice and a stratification factor in prospective clinical trials with ICIs.
Journal ArticleDOI
Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples
Marco Russano,Andrea Napolitano,Giulia Ribelli,Michele Iuliani,Sonia Simonetti,Fabrizio Citarella,Francesco Pantano,Emanuela Dell'Aquila,Cecilia Anesi,Nicola Silvestris,Antonella Argentiero,Antonio Giovanni Solimando,Bruno Vincenzi,Giuseppe Tonini,Daniele Santini +14 more
TL;DR: The current and possibly future applications of blood-based liquid biopsy in oncology, its advantages and its limitations in clinical practice are discussed, specifically focused on its role as a tool to capture tumor heterogeneity in metastatic cancer patients.
Journal ArticleDOI
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study
Alessio Cortellini,Sebastiano Buti,Daniele Santini,Fabiana Perrone,Raffaele Giusti,Marcello Tiseo,Melissa Bersanelli,Maria Michiara,Antonino Grassadonia,Davide Brocco,Nicola Tinari,Michele De Tursi,Federica Zoratto,Enzo Veltri,Riccardo Marconcini,Francesco Malorgio,Carlo Garufi,Marco Russano,Cecilia Anesi,Tea Zeppola,Marco Filetti,Paolo Marchetti,Andrea Botticelli,Gian Carlo Antonini Cappellini,Federica De Galitiis,Maria Giuseppa Vitale,Roberto Sabbatini,Sergio Bracarda,Rossana Berardi,Silvia Rinaldi,Marianna Tudini,Rosa Rita Silva,Annagrazia Pireddu,Francesco Atzori,Rita Chiari,Biagio Ricciuti,Daniela Iacono,Maria Rita Migliorino,Antonio Rossi,Giampiero Porzio,Katia Cannita,Valeria Ciciarelli,Maria Concetta Fargnoli,Paolo A. Ascierto,Corrado Ficorella +44 more
TL;DR: The finding of a greater incidence of irAEs among female patients ranks among the "hot topics" in gender-related differences in immuno-oncology.
Journal ArticleDOI
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice
Alessio Cortellini,Marco Tucci,Vincenzo Adamo,Luigia Stefania Stucci,Alessandro Russo,Enrica Teresa Tanda,Francesco Spagnolo,Francesca Rastelli,R. Bisonni,Daniele Santini,Marco Russano,Cecilia Anesi,Raffaele Giusti,Marco Filetti,Paolo Marchetti,Andrea Botticelli,Alain Gelibter,Mario Occhipinti,Riccardo Marconcini,Maria Giuseppa Vitale,Linda Nicolardi,Rita Chiari,Claudia Bareggi,Olga Nigro,Alessandro Tuzi,Michele De Tursi,Nicola Petragnani,Laura Pala,Sergio Bracarda,Serena Macrini,Alessandro Inno,Federica Zoratto,Enzo Veltri,Barbara Di Cocco,Domenico Mallardo,Maria Grazia Vitale,David J. Pinato,Giampiero Porzio,Corrado Ficorella,Paolo A. Ascierto +39 more
TL;DR: The association between baseline steroids administered for cancer-related indication, systemic antibiotics, PPIs and worse clinical outcomes with PD-1/PD-L1 checkpoint inhibitors is confirmed, which can be assumed to have immune-modulating detrimental effects.
Journal ArticleDOI
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients
Alessio Cortellini,Rita Chiari,Biagio Ricciuti,Giulio Metro,Fabiana Perrone,Marcello Tiseo,Melissa Bersanelli,Paola Bordi,Daniele Santini,Raffaele Giusti,Antonino Grassadonia,Pietro Di Marino,N. Tinari,Michele De Tursi,Federica Zoratto,Enzo Veltri,Francesco Malorgio,Carlo Garufi,Marco Russano,Cecilia Anesi,Tea Zeppola,Marco Filetti,Paolo Marchetti,Rossana Berardi,Silvia Rinaldi,Marianna Tudini,Rosa Rita Silva,Annagrazia Pireddu,Francesco Atzori,Daniela Iacono,Maria Rita Migliorino,Giampiero Porzio,Katia Cannita,Corrado Ficorella,Sebastiano Buti +34 more
TL;DR: It is confirmed that irAEs are concordantly related to higher ORR, longer PFS, and longer OS with anti-PD-1 immunotherapy in patients with NSCLC.